Eli Lilly's sees strength in 2017, shares take off

AP News
Posted: Dec 15, 2016 9:18 AM

Eli Lilly shares are up sharply after it laid out a better-than-expected 2017 forecast nearly a month after it had announced the failure of a key Alzheimer's treatment in testing.

Lilly said Thursday that it expects adjusted earnings to range between $4.05 and $4.15 per share next year on revenue of $21.8 billion to $22.3 billion.

Industry analysts polled by FactSet expect earnings of $3.96 per share on $21.68 billion in revenue.

The outlook represents growth from the company's 2016 forecast for adjusted earnings of $3.50 to $3.60 per share on $20.8 billion to $21.2 billion in revenue.

What Is John Brennan Hiding?
Sheriff David Clarke (Ret.)

The Indianapolis company expects that growth to come from new drugs and established products like the insulin Humalog.

Shares of Eli Lilly and Co. climbed 4 percent to $70.38 in early trading.